Innovator Warner Chilcott Limited announced (announced in a press release Here) that it has received two Paragraph IV Certification Notices from Indian generic player Lupin. The Paragraph IV Certification Notices advise the Company of the filing of Abbreviated New Drug Applications (ANDAs) by Lupin for generic versions of the Company's oral contraceptives Loestrin 24 Fe (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets) and Femcon Fe (norethindrone, ethinyl estradiol tablets, chewable, ferrous fumarate tablets)
Loestrin 24 Fe, which was launched in March of 2006, is protected by US5552394 which expires in 2014.
Femcon Fe, which was introduced by the Company during the second half of 2006, is protected by US6,667,050 which expires in 2019.
Earlier, innovator settled it’s pending litigation with Watson as reported by us Here
No comments:
Post a Comment